Homepage > Immunology
iQone Healthcare's Immunology franchise is committed to bring new prescription medicines including biosimilar products on the market to treat patients with several autoimmune disorders. Autoimmune disorders occur when the immune system of the body attacks and destroys its own healthy body tissue. iQone Healthcare is marketing Remsima® (infliximab), the first biosimilar monoclonal antibody approved in Europe and Switzerland. Remsima® gives the chance to treat patients with biosimilar products that helps to relieve the spending burden to them and to the healthcare system.
iQone Healthcare's experience in pharmaceutical products reaches back 35 years. iQone Healthcare is a secure, trustworthy partner with activities covering every aspects of new immunology drug market entry and commercialisation including medical expertise in Europe. Therefore iQone Healthcare is a partner of choice for international biopharmaceutical specialty companies seeking to penetrate efficiently the European market.
Adverse Event Reporting
Product Quality Complaint Reporting
Medical Information Questions
If you would like to report an adverse event reaction relating to the use of Remsima® or a product quality complaint or if you have a medical enquiry, please contact us as follows:
Phone: +41 22 510 2929
Fax: +41 22 510 2928
Lines are open Monday-Friday, 9am-5pm. Outside of these office hours, on weekends and on bank holidays your call will be diverted to an answering machine. Please leave a message including your contact details for follow-ups. Alternatively you can complete the so- called Remsima Reporting and Request Form.
A response will be given within a short period of time.
iQone Healthcare cannot provide advice on personal medical matters if you are a patient. Such questions should be discussed with your treating physician.
Today innovative treatments are being developed that bring hope to patients around the world by targeting cancer cells with greater precision and fewer side effects.